Antidepressant pharmacogenetics represents a stimulating, but often discouraging field. The present study proposes a combination of several methodologies across three independent samples. Genes belonging to monoamine, neuroplasticity, circadian rhythm and transcription factor pathways were investigated in two samples (n=369 and 88) with diagnosis of major depression who were treated with antidepressants. Phenotypes were response, remission and treatment-resistant depression. Logistic regression including appropriate covariates was performed. Genes associated with outcomes were investigated in the STAR∗D (Sequenced Treatment Alternatives to Relieve Depression) genome-wide study (n=1861). Top genes were further studied through a pathway analy...
Objective Recent evidence suggests that signalling cascades located downstream of monoamine receptor...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
A candidate gene and a genome-wide approach were combined to study the pharmacogenetics of antidepre...
Antidepressant pharmacogenetics represents a stimulating, but often discouraging field. The present ...
none2noThe pharmacogenetics of antidepressants has been not only a challenging but also frustrating ...
Despite numerous studies on major depressive disorder (MDD) susceptibility, the precise underlying m...
Background Antidepressant drugs are used as first-line treatment in depression, but response has bee...
Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and up to 30% do ...
Genes belonging to neuroplasticity, monoamine, circadian rhythm, and transcription factor pathways w...
BackgroundAntidepressant drugs are used as first-line treatment in depression, but response has been...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
none5noIntroduction: Depression is responsible for the most part of the personal and socio-economic ...
none3noDepression leads the higher personal and socio-economical burden within psychiatric disorders...
The past few decades have witnessed much progress in the field of pharmacogenetics. The identificati...
Objective Recent evidence suggests that signalling cascades located downstream of monoamine receptor...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
A candidate gene and a genome-wide approach were combined to study the pharmacogenetics of antidepre...
Antidepressant pharmacogenetics represents a stimulating, but often discouraging field. The present ...
none2noThe pharmacogenetics of antidepressants has been not only a challenging but also frustrating ...
Despite numerous studies on major depressive disorder (MDD) susceptibility, the precise underlying m...
Background Antidepressant drugs are used as first-line treatment in depression, but response has bee...
Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and up to 30% do ...
Genes belonging to neuroplasticity, monoamine, circadian rhythm, and transcription factor pathways w...
BackgroundAntidepressant drugs are used as first-line treatment in depression, but response has been...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
none5noIntroduction: Depression is responsible for the most part of the personal and socio-economic ...
none3noDepression leads the higher personal and socio-economical burden within psychiatric disorders...
The past few decades have witnessed much progress in the field of pharmacogenetics. The identificati...
Objective Recent evidence suggests that signalling cascades located downstream of monoamine receptor...
Genome-wide association studies have generally failed to identify polymorphisms associated with anti...
A candidate gene and a genome-wide approach were combined to study the pharmacogenetics of antidepre...